Skip to main content
Journal cover image

Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration.

Publication ,  Journal Article
Riedel, RF
Published in: Lancet Oncol
January 2019

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet Oncol

DOI

EISSN

1474-5488

Publication Date

January 2019

Volume

20

Issue

1

Start / End Page

14 / 15

Location

England

Related Subject Headings

  • Sulfonamides
  • Solitary Fibrous Tumors
  • Pyrimidines
  • Oncology & Carcinogenesis
  • Indazoles
  • Immunotherapy
  • Humans
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Riedel, R. F. (2019). Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration. Lancet Oncol, 20(1), 14–15. https://doi.org/10.1016/S1470-2045(18)30745-9
Riedel, Richard F. “Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration.Lancet Oncol 20, no. 1 (January 2019): 14–15. https://doi.org/10.1016/S1470-2045(18)30745-9.
Riedel, Richard F. “Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration.Lancet Oncol, vol. 20, no. 1, Jan. 2019, pp. 14–15. Pubmed, doi:10.1016/S1470-2045(18)30745-9.
Journal cover image

Published In

Lancet Oncol

DOI

EISSN

1474-5488

Publication Date

January 2019

Volume

20

Issue

1

Start / End Page

14 / 15

Location

England

Related Subject Headings

  • Sulfonamides
  • Solitary Fibrous Tumors
  • Pyrimidines
  • Oncology & Carcinogenesis
  • Indazoles
  • Immunotherapy
  • Humans
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis